318 related articles for article (PubMed ID: 33470843)
1. Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Flickinger JC; Rappaport JA; Barton JR; Baybutt TR; Pattison AM; Snook AE; Waldman SA
Biomark Med; 2021 Feb; 15(3):201-217. PubMed ID: 33470843
[TBL] [Abstract][Full Text] [Related]
2. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Entezari AA; Snook AE; Waldman SA
Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
[TBL] [Abstract][Full Text] [Related]
3. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
4. Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer.
Caspi A; Entezari AA; Crutcher M; Snook AE; Waldman SA
Per Med; 2022 Sep; 19(5):457-472. PubMed ID: 35920071
[TBL] [Abstract][Full Text] [Related]
5. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
Marszalowicz GP; Snook AE; Magee MS; Merlino D; Berman-Booty LD; Waldman SA
Oncotarget; 2014 Oct; 5(19):9460-71. PubMed ID: 25294806
[TBL] [Abstract][Full Text] [Related]
6. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
[TBL] [Abstract][Full Text] [Related]
7. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
8. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
9. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.
Danaee H; Kalebic T; Wyant T; Fassan M; Mescoli C; Gao F; Trepicchio WL; Rugge M
PLoS One; 2017; 12(12):e0189953. PubMed ID: 29261789
[TBL] [Abstract][Full Text] [Related]
10. The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.
Baybutt TR; Aka AA; Snook AE
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28914772
[TBL] [Abstract][Full Text] [Related]
11. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.
Weinberg DS; Foster NR; Della'Zanna G; McMurray RP; Kraft WK; Pallotto A; Kastenberg DM; Katz LC; Henry CH; Moleski SM; Limburg PJ; Waldman SA
Cancer Biol Ther; 2021 Dec; 22(10-12):544-553. PubMed ID: 34632925
[TBL] [Abstract][Full Text] [Related]
12. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Weinberg DS; Lin JE; Foster NR; Della'Zanna G; Umar A; Seisler D; Kraft WK; Kastenberg DM; Katz LC; Limburg PJ; Waldman SA
Cancer Prev Res (Phila); 2017 Jun; 10(6):345-354. PubMed ID: 28396341
[TBL] [Abstract][Full Text] [Related]
13. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
[TBL] [Abstract][Full Text] [Related]
14. Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3.
Rampuria P; Mosyak L; Root AR; Svenson K; Agostino MJ; LaVallie ER
Sci Rep; 2023 Aug; 13(1):13408. PubMed ID: 37591971
[TBL] [Abstract][Full Text] [Related]
15. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
[TBL] [Abstract][Full Text] [Related]
17. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
Birbe R; Palazzo JP; Walters R; Weinberg D; Schulz S; Waldman SA
Hum Pathol; 2005 Feb; 36(2):170-9. PubMed ID: 15754294
[TBL] [Abstract][Full Text] [Related]
18. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
19. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.
Lisby AN; Flickinger JC; Bashir B; Weindorfer M; Shelukar S; Crutcher M; Snook AE; Waldman SA
Expert Rev Precis Med Drug Dev; 2021; 6(2):117-129. PubMed ID: 34027103
[TBL] [Abstract][Full Text] [Related]
20. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
